These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 32515665)
21. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments. Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189 [TBL] [Abstract][Full Text] [Related]
22. Management of Axial Spondyloarthritis - Insights into Upadacitinib. Braun J; Kiltz U; Baraliakos X Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520 [TBL] [Abstract][Full Text] [Related]
23. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Zeng X; Zhao D; Radominski SC; Keiserman M; Lee CK; Meerwein S; Enejosa J; Sui Y; Mohamed MF; Park W Int J Rheum Dis; 2021 Dec; 24(12):1530-1539. PubMed ID: 34779576 [TBL] [Abstract][Full Text] [Related]
24. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis. Law CCY; Kayal M; Mehandru S; Colombel JF Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073 [TBL] [Abstract][Full Text] [Related]
26. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801 [TBL] [Abstract][Full Text] [Related]
28. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Fukui S; Kawaai S; Sawada H; Kishimoto M Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181 [TBL] [Abstract][Full Text] [Related]
29. Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome. Tanaka Y Expert Opin Pharmacother; 2023; 24(16):1791-1798. PubMed ID: 37563102 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824 [TBL] [Abstract][Full Text] [Related]
31. The role of upadacitinib for the treatment of axial spondyloarthritis. George N; Liew JW; Dubreuil M Immunotherapy; 2023 Oct; 15(15):1227-1237. PubMed ID: 37675498 [TBL] [Abstract][Full Text] [Related]
32. Clinical use of Jak 1 inhibitors for rheumatoid arthritis. Nash P Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii31-ii38. PubMed ID: 33950231 [TBL] [Abstract][Full Text] [Related]
33. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Keeling S; Maksymowych WP Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642 [TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116 [TBL] [Abstract][Full Text] [Related]
35. Evaluating upadacitinib for the treatment of psoriatic arthritis. Akpabio A; Adebajo A Expert Opin Pharmacother; 2022 Feb; 23(2):169-173. PubMed ID: 35014922 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. Fleischmann R; Meerwein S; Charles-Schoeman C; Combe B; Hall S; Khan N; Carter KM; Camp HS; Rubbert-Roth A RMD Open; 2024 Jul; 10(3):. PubMed ID: 39059811 [TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. Ho Lee Y; Gyu Song G J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356 [TBL] [Abstract][Full Text] [Related]
38. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649 [TBL] [Abstract][Full Text] [Related]
39. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798 [TBL] [Abstract][Full Text] [Related]